A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin
NCT07796477 on ClinicalTrials.gov · last registry update 2026-09-01
An unusually large phase 2: 240 participants, more than double the 114 typical for the stage. Due to report 28 September 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Change from baseline in Hemoglobin A1c (HbA1c). Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.
- Status
- NOT_YET_RECRUITING
- Phase
- P2
- Drug
- tirzepatideZepbound, Mounjaro
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Sponsor type
- Industry
- Enrollment
- 240
- Started
- 2026-11-06
- Primary completion
- 2027-09-28 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-09-01 | First seen in registry | Registered as NOT_YET_RECRUITING, P2 |
Primary outcome
Change from baseline in Hemoglobin A1c (HbA1c)
Conditions studied
T2DM (Type 2 Diabetes Mellitus)
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.